Humoral response to mRNA‐based COVID‐19 vaccine in patients with immune thrombocytopenia

Data for COVID‐19 vaccine response in patients with immune thrombocytopenia (ITP) are very limited. In a study of 28 patients with ITP, anti‐severe acute respiratory syndrome coronavirus 2 spike antibody titres were measured after vaccination. The seroconversion rate for ITP patients was 91.3%, comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Akio, Onozawa, Masahiro, Kobayashi, Mirei, Tsukamoto, Shihori, Senjo, Hajime, Ishio, Takashi, Yokoyama, Emi, Izumiyama, Koh, Saito, Makoto, Muraki, Haruna, Morioka, Masanobu, Teshima, Takanori, Kondo, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877767/
https://www.ncbi.nlm.nih.gov/pubmed/36442510
http://dx.doi.org/10.1111/bjh.18578
Descripción
Sumario:Data for COVID‐19 vaccine response in patients with immune thrombocytopenia (ITP) are very limited. In a study of 28 patients with ITP, anti‐severe acute respiratory syndrome coronavirus 2 spike antibody titres were measured after vaccination. The seroconversion rate for ITP patients was 91.3%, comparable to that in healthy controls (HCs). However, the antibody titre in ITP patients was significantly lower than that in HCs and declined with ageing. Furthermore, the antibody titre in ITP patients who received a minimum prednisolone dose of at least 5 mg/day at any time‐point at or after initial vaccination was lower than that in other patients.

Ejemplares similares